The rationale to combine cabozantinib with telaglenastat was based in part on observations that cabozantinib decreases glucose uptake measured via FDG-PET (coinciding with decreased expression of GLUT1/3) in thyroid cancer cells [24] and in animal models of colorectal cancer [25]. Here, SLC2A1 is linked to colorectal cancer.